GlassScriptPhysician profile
Laura Flusche
NPI 1013616374
$1,438.20
in general payments reported to CMS, 2019-2025
17 companies · $512 in 2025
The $512 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $156 · 2024: $770 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $304.76 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $209.78 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $185.19 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $126.22 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $108.36 | 2024-2025 | Jardiance, Mounjaro, Kisunla |
| Teva Pharmaceuticals USA, INC. | $102.97 | 2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.78 | 2024-2025 | Jardiance |
| Abbvie INC. | $68.41 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.21 | 2025 | Caplyta |
| Pfizer INC. | $43.61 | 2024 | |
| Astellas Pharma US INC | $37.73 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $32.72 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.18 | 2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $19.04 | 2024 | Keveyis |
| Amgen INC. | $18.24 | 2025 | Repatha |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.58 | 2025 | Voquezna |
| Exact Sciences Corporation | $17.42 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Flusche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.